SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — May 21, 2019
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: May 21, 2019 · CIK: 0001213037 · Accession: 0001104659-19-030676
AI Filing Summary & Sentiment
File numbers found in text: 333-224808
Referenced dates: May 20, 2019
Letter
Division of Corporation Finance Securities and Exchange Commission Attention: Jeffrey Gabor Post-Effective Amendment No. 3 to Form S-1 Filed May 17, 2019 File No. 333-224808
Re: Trovagene, Inc.
Dear Mr. Gabor:
This letter sets forth the response of Trovagene, Inc., a Delaware corporation (the “Company” or “we”), to the comment received from the Staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) by letter dated May 20, 2019 (“Comments Letter”) concerning the Company’s Post-Effective Amendment No. 3 to Form S-1 (the “Registration Statement”).
Post-Effective Amendment No. 3 to Form S-1
General
1. Please revise to include a complete prospectus that includes all of the disclosure items required by Part I. Refer to Securities Act Rule 472(b).
Response: We have revised Post-Effective Amendment No. 3 to Form S-1 to include a complete prospectus.
* * * *
If you have any further comments and/or questions, please contact me at (212) 634-3067.
Very truly yours,
/s/ Jeffrey Fessler
Show Raw Text
CORRESP 1 filename1.htm May 21, 2019 Division of Corporation Finance Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Jeffrey Gabor Re: Trovagene, Inc. Post-Effective Amendment No. 3 to Form S-1 Filed May 17, 2019 File No. 333-224808 Dear Mr. Gabor: This letter sets forth the response of Trovagene, Inc., a Delaware corporation (the “Company” or “we”), to the comment received from the Staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) by letter dated May 20, 2019 (“Comments Letter”) concerning the Company’s Post-Effective Amendment No. 3 to Form S-1 (the “Registration Statement”). Post-Effective Amendment No. 3 to Form S-1 General 1. Please revise to include a complete prospectus that includes all of the disclosure items required by Part I. Refer to Securities Act Rule 472(b). Response: We have revised Post-Effective Amendment No. 3 to Form S-1 to include a complete prospectus. * * * * If you have any further comments and/or questions, please contact me at (212) 634-3067. Very truly yours, /s/ Jeffrey Fessler 1